Simpson B J, Weatherill J, Miller E P, Lessells A M, Langdon S P, Miller W R
ICRF Medical Oncology Unit, Western General Hospitals NHS Trust, Edinburgh, UK.
Br J Cancer. 1995 Apr;71(4):758-62. doi: 10.1038/bjc.1995.147.
In this study the expression of c-erbB-3 protein was investigated in a range of human ovarian tumours using a monoclonal antibody (RTJ1) raised to a synthetic peptide from the cytoplasmic domain of the human c-erbB-3 protein. A total of 73 samples from 71 patients were graded as negative, weak, moderate or strong according to the intensity of immunohistochemical staining observed, and this was related to tumour characteristics and other clinical parameters. In terms of positivity vs negativity, of the 73 samples examined, 62 (85%) showed positive immunohistochemical staining for c-erbB-3. The majority of all ovarian tumours studied were positive for c-erbB-3 regardless of whether they were malignant (89%), borderline (100%) or benign (61%), however the incidence of positivity was significantly less in the benign group than in overtly malignant tumours (P = 0.03). c-erbB-3 positivity was not significantly associated with either age at diagnosis, tumour stage, differentiation, ploidy, percentage in S-phase or post-operative tumour bulk in malignant tumours. In terms of intensity of staining no significant difference was observed either within the common epithelial group or between this group and tumours of a benign nature. A significantly more intense pattern of c-erbB-3 staining was observed in tumours of borderline malignancy when compared with their overtly malignant counterparts (P = 0.002). Patients presenting with early-stage malignant tumours (I/II) were more likely to display intense tumour staining than those with late-stage disease (III/IV) (P = 0.04). These investigations suggest that c-erbB-3 protein is frequently expressed in both benign and malignant ovarian tumours, and that overexpression is more common in borderline and early invasive lesions.
在本研究中，使用针对人c-erbB-3蛋白胞质结构域合成肽产生的单克隆抗体（RTJ1），研究了一系列人卵巢肿瘤中c-erbB-3蛋白的表达。根据观察到的免疫组化染色强度，对来自71例患者的73个样本进行分级，分为阴性、弱阳性、中等阳性或强阳性，并将其与肿瘤特征和其他临床参数相关联。在所检测的73个样本中，就阳性与阴性而言，62个（85%）显示c-erbB-3免疫组化染色阳性。无论肿瘤是恶性（89%）、交界性（100%）还是良性（61%），所研究的所有卵巢肿瘤大多数c-erbB-3呈阳性，然而，良性组的阳性发生率明显低于明显恶性肿瘤（P = 0.03）。c-erbB-3阳性与恶性肿瘤的诊断年龄、肿瘤分期、分化程度、倍体、S期百分比或术后肿瘤体积均无显著相关性。就染色强度而言，在常见上皮组内或该组与良性肿瘤之间均未观察到显著差异。与明显恶性的对应肿瘤相比，交界性恶性肿瘤中观察到c-erbB-3染色模式明显更强（P = 0.002）。早期恶性肿瘤（I/II期）患者比晚期疾病（III/IV期）患者更有可能表现出强烈的肿瘤染色（P = 0.04）。这些研究表明，c-erbB-3蛋白在良性和恶性卵巢肿瘤中均频繁表达，且过表达在交界性和早期浸润性病变中更为常见。
